Altimmune
ALT
41 hedge funds and large institutions have $6.83M invested in Altimmune in 2017 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 42 closing their positions.
0.46% more ownership
Funds ownership: 0% → 0.46% (+0.46%)
25% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 12
42% less funds holding
Funds holding: 71 → 41 (-30)
66% less capital invested
Capital invested by funds: $20.3M → $6.83M (-$13.5M)
71% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 42
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $387K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.01M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$620K |
| 3 |
Millennium Management
New York
|
+$588K |
| 4 |
ECM
Element Capital Management
New York
|
+$262K |
| 5 |
Goldman Sachs
New York
|
+$188K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.33M |
| 2 |
State Street
Boston,
Massachusetts
|
-$738K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$659K |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
-$411K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$305K |
ALT Hedge Fund Activity: Q2 2017 in Review
41 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q2 2017, worth a combined $6.83M — down 66% from $20.3M a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of ALT and 12 opened new positions — a net loss of 30 holders — while 12 trimmed existing stakes and 9 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.01M. The largest seller was BlackRock, cutting an estimated $1.33M.
- 41 institutional investors held Altimmune (ALT) as of Q2 2017, down from 71 in Q1 2017.
- Funds reported $6.83M of Altimmune stock for Q2 2017, down 66% quarter-over-quarter.
- 12 funds opened new Altimmune positions in Q2 2017 and 42 closed out, a net change of -30 holders.
- The largest Altimmune buyer in Q2 2017 was Renaissance Technologies, an estimated $1.01M added.
- The largest Altimmune seller in Q2 2017 was BlackRock, an estimated $1.33M sold.
Based on aggregated 13F filings for Q2 2017.